JP2022534402A5 - - Google Patents

Info

Publication number
JP2022534402A5
JP2022534402A5 JP2021570170A JP2021570170A JP2022534402A5 JP 2022534402 A5 JP2022534402 A5 JP 2022534402A5 JP 2021570170 A JP2021570170 A JP 2021570170A JP 2021570170 A JP2021570170 A JP 2021570170A JP 2022534402 A5 JP2022534402 A5 JP 2022534402A5
Authority
JP
Japan
Prior art keywords
rnai construct
construct according
scap
nucleotides
antisense strand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021570170A
Other languages
English (en)
Japanese (ja)
Other versions
JP7763104B2 (ja
JP2022534402A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/035545 external-priority patent/WO2020243702A2/en
Publication of JP2022534402A publication Critical patent/JP2022534402A/ja
Publication of JP2022534402A5 publication Critical patent/JP2022534402A5/ja
Priority to JP2025176137A priority Critical patent/JP2026016500A/ja
Application granted granted Critical
Publication of JP7763104B2 publication Critical patent/JP7763104B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021570170A 2019-05-30 2020-06-01 SCAP発現を阻害するためのRNAiコンストラクト及びその使用方法 Active JP7763104B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025176137A JP2026016500A (ja) 2019-05-30 2025-10-20 SCAP発現を阻害するためのRNAiコンストラクト及びその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962854433P 2019-05-30 2019-05-30
US62/854,433 2019-05-30
PCT/US2020/035545 WO2020243702A2 (en) 2019-05-30 2020-06-01 Rnai constructs for inhibiting scap expression and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025176137A Division JP2026016500A (ja) 2019-05-30 2025-10-20 SCAP発現を阻害するためのRNAiコンストラクト及びその使用方法

Publications (3)

Publication Number Publication Date
JP2022534402A JP2022534402A (ja) 2022-07-29
JP2022534402A5 true JP2022534402A5 (cg-RX-API-DMAC7.html) 2023-06-05
JP7763104B2 JP7763104B2 (ja) 2025-10-31

Family

ID=71833431

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021570170A Active JP7763104B2 (ja) 2019-05-30 2020-06-01 SCAP発現を阻害するためのRNAiコンストラクト及びその使用方法
JP2025176137A Pending JP2026016500A (ja) 2019-05-30 2025-10-20 SCAP発現を阻害するためのRNAiコンストラクト及びその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025176137A Pending JP2026016500A (ja) 2019-05-30 2025-10-20 SCAP発現を阻害するためのRNAiコンストラクト及びその使用方法

Country Status (17)

Country Link
US (1) US20220307022A1 (cg-RX-API-DMAC7.html)
EP (1) EP3976786A2 (cg-RX-API-DMAC7.html)
JP (2) JP7763104B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220016138A (cg-RX-API-DMAC7.html)
CN (2) CN113924368B (cg-RX-API-DMAC7.html)
AR (1) AR119061A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020284254A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021024080A2 (cg-RX-API-DMAC7.html)
CA (1) CA3141902A1 (cg-RX-API-DMAC7.html)
CL (2) CL2021003169A1 (cg-RX-API-DMAC7.html)
EA (1) EA202193296A1 (cg-RX-API-DMAC7.html)
IL (1) IL288398A (cg-RX-API-DMAC7.html)
MX (2) MX2021014465A (cg-RX-API-DMAC7.html)
SG (1) SG11202113112WA (cg-RX-API-DMAC7.html)
TW (1) TW202111124A (cg-RX-API-DMAC7.html)
UY (1) UY38733A (cg-RX-API-DMAC7.html)
WO (1) WO2020243702A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025512445A (ja) * 2022-04-15 2025-04-17 ディセルナ ファーマシューティカルズ インコーポレイテッド Scap活性を調節するための組成物及び方法
CA3257118A1 (en) * 2022-05-25 2023-11-30 Amgen Inc. Arni constructions to inhibit Scap expression and their methods of use
IL317824A (en) * 2022-07-11 2025-02-01 Sanegene Bio Usa Inc Ribose derivatives modified at the '2' position and methods of use
KR20250043473A (ko) * 2022-07-27 2025-03-28 이-테라퓨틱스 피엘씨 핵산 화합물
CN117757790A (zh) * 2022-11-17 2024-03-26 北京福元医药股份有限公司 抑制SCAP基因表达的siRNA、其缀合物和药物组合物及用途

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
DE69233087T2 (de) 1991-11-22 2003-12-24 Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) Verfahren zur Herstellung von Polymerarrays
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5840710A (en) 1994-12-09 1998-11-24 Genzyme Corporation Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules
US5981501A (en) 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5545531A (en) 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
JP4335310B2 (ja) 1995-06-07 2009-09-30 ザ ユニバーシティ オブ ブリティッシュ コロンビア 疎水性脂質−核酸複合中間体を通して調製される脂質−核酸粒子、及び遺伝子移送のための使用
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US6217900B1 (en) 1997-04-30 2001-04-17 American Home Products Corporation Vesicular complexes and methods of making and using the same
WO1999001579A1 (en) 1997-07-01 1999-01-14 Isis Pharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
ATE237312T1 (de) 1998-07-20 2003-05-15 Protiva Biotherapeutics Inc In liposomen verkapselte nukleinsäurekomplexe
US7491805B2 (en) 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US7833992B2 (en) 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
US6693187B1 (en) 2000-10-17 2004-02-17 Lievre Cornu Llc Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge
US20030130186A1 (en) 2001-07-20 2003-07-10 Chandra Vargeese Conjugates and compositions for cellular delivery
US7109165B2 (en) 2001-05-18 2006-09-19 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
CA2487274A1 (en) 2002-05-06 2003-11-13 Nucleonics Inc. Spermine chemically linked to lipids and cell-specific targeting molecules as a transfection agent
US7723509B2 (en) 2003-04-17 2010-05-25 Alnylam Pharmaceuticals IRNA agents with biocleavable tethers
US7851615B2 (en) 2003-04-17 2010-12-14 Alnylam Pharmaceuticals, Inc. Lipophilic conjugated iRNA agents
US8017762B2 (en) 2003-04-17 2011-09-13 Alnylam Pharmaceuticals, Inc. Modified iRNA agents
EP2669377A3 (en) 2003-04-17 2015-10-14 Alnylam Pharmaceuticals Inc. Modified iRNA agents
WO2008036638A2 (en) * 2006-09-18 2008-03-27 Alnylam Pharmaceuticals, Inc. Rnai modulation of scap and therapeutic uses thereof
WO2008131419A2 (en) 2007-04-23 2008-10-30 Alnylam Pharmaceuticals, Inc. Glycoconjugates of rna interference agents
EP2229186A2 (en) 2007-12-04 2010-09-22 Alnylam Pharmaceuticals Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
AR090905A1 (es) 2012-05-02 2014-12-17 Merck Sharp & Dohme Conjugados que contienen tetragalnac y peptidos y procedimientos para la administracion de oligonucleotidos, composicion farmaceutica
WO2014205451A2 (en) 2013-06-21 2014-12-24 Isis Pharmaceuticals, Inc. Compositions and methods for modulation of target nucleic acids
IL316808A (en) * 2014-08-20 2025-01-01 Alnylam Pharmaceuticals Inc Modified double-stranded RNA materials and their uses
EP3387129A1 (en) * 2015-12-10 2018-10-17 Alnylam Pharmaceuticals, Inc. STEROL REGULATORY ELEMENT BINDING PROTEIN (SREBP) CHAPERONE (SCAP) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
UY37376A (es) * 2016-08-26 2018-03-23 Amgen Inc Construcciones de arni para inhibir expresión de asgr1 y métodos para su uso
US10450565B2 (en) * 2017-01-10 2019-10-22 Arrowhead Pharmaceuticals, Inc. Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use

Similar Documents

Publication Publication Date Title
US11591598B2 (en) Oligomers and oligomer conjugates
JP2023537943A5 (cg-RX-API-DMAC7.html)
JP2023103244A5 (cg-RX-API-DMAC7.html)
JP2021506238A5 (cg-RX-API-DMAC7.html)
JP2022501040A5 (cg-RX-API-DMAC7.html)
JP4718379B2 (ja) 修飾された低分子干渉rna分子および使用方法
CN105377887B (zh) 用于调节载脂蛋白(a)表达的组合物和方法
JP2022511550A5 (cg-RX-API-DMAC7.html)
JP6492053B2 (ja) 修飾tgf−ベータオリゴヌクレオチド
TWI881004B (zh) 用於治療hbv之靶向hbv的治療性寡核苷酸及tlr7促效劑之醫藥組合
JP2024105284A5 (cg-RX-API-DMAC7.html)
JP2017512502A (ja) 新規の二重らせんオリゴrnaおよびこれを含む線維症または呼吸器疾患の予防または治療用薬学組成物
WO2022068923A1 (zh) 血管生成素样3(ANGPTL3)的siRNA及其用途
JP2024538859A5 (cg-RX-API-DMAC7.html)
CN111378655A (zh) 抑制CTGF基因表达的siRNA、含有该siRNA的药物组合物及其用途
JP2024528701A5 (cg-RX-API-DMAC7.html)
JP2024512635A5 (cg-RX-API-DMAC7.html)
JP2015532100A (ja) アンフィレギュリンに特異的な二重鎖オリゴrna、そのような二重鎖オリゴrnaを含む二重鎖オリゴrnaの構造体及びこれを含む呼吸器疾患の予防または治療用の組成物
JP2024543195A5 (cg-RX-API-DMAC7.html)
JP2025512771A5 (cg-RX-API-DMAC7.html)
JP2023503121A (ja) Ctgf遺伝子特異的二重鎖オリゴヌクレオチド及びこれを含む線維症関連疾患及び呼吸器関連疾患の予防及び治療用組成物
KR20260040626A (ko) 안지오텐시노겐을 표적으로 하는 올리고뉴클레오티드 및 이의 용도
WO2023213284A1 (zh) 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
JP2025517965A5 (cg-RX-API-DMAC7.html)
JP2023506547A (ja) B型肝炎ウイルス感染を処置するためのcops3阻害剤の使用